Cargando…
Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept t...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529895/ https://www.ncbi.nlm.nih.gov/pubmed/26273623 http://dx.doi.org/10.1155/2015/504208 |
_version_ | 1782384835294134272 |
---|---|
author | Lv, Qing Li, Qiuxia Zhang, Peizhuo Jiang, Yingjuan Wang, Xinwei Wei, Qiujing Cao, Shuangyan Liao, Zetao Lin, Zhiming Pan, Yunfeng Huang, Jianlin Li, Tianwang Jin, Ou Wu, Yuqiong Gu, Jieruo |
author_facet | Lv, Qing Li, Qiuxia Zhang, Peizhuo Jiang, Yingjuan Wang, Xinwei Wei, Qiujing Cao, Shuangyan Liao, Zetao Lin, Zhiming Pan, Yunfeng Huang, Jianlin Li, Tianwang Jin, Ou Wu, Yuqiong Gu, Jieruo |
author_sort | Lv, Qing |
collection | PubMed |
description | Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR. Conclusion. AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS. |
format | Online Article Text |
id | pubmed-4529895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-45298952015-08-13 Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets Lv, Qing Li, Qiuxia Zhang, Peizhuo Jiang, Yingjuan Wang, Xinwei Wei, Qiujing Cao, Shuangyan Liao, Zetao Lin, Zhiming Pan, Yunfeng Huang, Jianlin Li, Tianwang Jin, Ou Wu, Yuqiong Gu, Jieruo Biomed Res Int Clinical Study Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR. Conclusion. AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS. Hindawi Publishing Corporation 2015 2015-07-26 /pmc/articles/PMC4529895/ /pubmed/26273623 http://dx.doi.org/10.1155/2015/504208 Text en Copyright © 2015 Qing Lv et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Lv, Qing Li, Qiuxia Zhang, Peizhuo Jiang, Yingjuan Wang, Xinwei Wei, Qiujing Cao, Shuangyan Liao, Zetao Lin, Zhiming Pan, Yunfeng Huang, Jianlin Li, Tianwang Jin, Ou Wu, Yuqiong Gu, Jieruo Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets |
title | Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets |
title_full | Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets |
title_fullStr | Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets |
title_full_unstemmed | Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets |
title_short | Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets |
title_sort | disorders of micrornas in peripheral blood mononuclear cells: as novel biomarkers of ankylosing spondylitis and provocative therapeutic targets |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529895/ https://www.ncbi.nlm.nih.gov/pubmed/26273623 http://dx.doi.org/10.1155/2015/504208 |
work_keys_str_mv | AT lvqing disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT liqiuxia disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT zhangpeizhuo disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT jiangyingjuan disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT wangxinwei disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT weiqiujing disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT caoshuangyan disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT liaozetao disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT linzhiming disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT panyunfeng disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT huangjianlin disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT litianwang disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT jinou disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT wuyuqiong disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets AT gujieruo disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets |